StockData
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock

CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$2.06−0.38 (-15.40%)

Close on Nov 20, 2026Market cap $39.84MP/E –Yield –

Corbus Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Corbus Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2023 was -$36.10M. For fiscal 2025 it was -$64.50M. The highest annual figure on record is -$2.43M in fiscal 2014.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$64.50M–
FY2024Dec 31, 2024-$41.79M–
FY2023Dec 31, 2023-$36.10M–
FY2022Dec 31, 2022-$37.56M–
FY2021Dec 31, 2021-$48.24M–
FY2020Dec 31, 2020-$100.17M–
FY2019Dec 31, 2019-$48.46M–
FY2018Dec 31, 2018-$32.37M–
FY2017Dec 31, 2017-$28.50M–
FY2016Dec 31, 2016-$13.92M–
FY2015Dec 31, 2015-$4.74M–
FY2014Dec 31, 2014-$2.43M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.63M–
Q1 FY2026Mar 31, 2026-$25.58M–
Q2 FY2025Jun 30, 2025-$16.60M–
Q1 FY2025Mar 31, 2025-$16.42M–
Q4 FY2023Dec 31, 2023-$6.01M–
Q3 FY2023Sep 30, 2023-$7.18M–
Q2 FY2023Jun 30, 2023-$7.80M–
Q1 FY2023Mar 31, 2023-$15.11M–
Q4 FY2022Dec 31, 2022-$7.45M–
Q3 FY2022Sep 30, 2022-$7.25M–
Q2 FY2022Jun 30, 2022-$12.23M–
Q1 FY2022Mar 31, 2022-$10.63M–
Q4 FY2021Dec 31, 2021-$9.76M–
Q4 FY2020Dec 31, 2020-$18.17M–
Q3 FY2020Sep 30, 2020-$27.31M–
Q2 FY2020Jun 30, 2020-$26.62M–
Q1 FY2020Mar 31, 2020-$28.06M-373.9%
Q4 FY2019Dec 31, 2019-$23.85M–
Q3 FY2019Sep 30, 2019-$18.28M–
Q2 FY2019Jun 30, 2019-$16.57M–
Q1 FY2019Mar 31, 2019$10.24M–
Q4 FY2018Dec 31, 2018-$14.31M–
Q3 FY2018Sep 30, 2018-$8.95M–
Q2 FY2018Jun 30, 2018-$6.23M–
Q1 FY2018Mar 31, 2018-$2.87M–
Q4 FY2017Dec 31, 2017-$9.69M–
Q3 FY2017Sep 30, 2017-$6.38M–
Q2 FY2017Jun 30, 2017-$5.76M–
Q1 FY2017Mar 31, 2017-$6.68M–
Q4 FY2016Dec 31, 2016-$5.57M–
Q3 FY2016Sep 30, 2016-$3.12M–

More Corbus Pharmaceuticals figures

See a number that looks wrong?